Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia

DOI Web Site PubMed 15 References
  • YAGO Kazuhiro
    Department of Internal Medicine, Division of Hematology/Oncology, Shizuoka General Hospital
  • ITOH Mitsuru
    Department of Internal Medicine, Division of Hematology/Oncology, Shizuoka General Hospital
  • SHIMADA Hideto
    Department of Internal Medicine, Division of Hematology/Oncology, Shizuoka General Hospital

Bibliographic Information

Other Title
  • HLA1座不適合同胞間同種骨髄移植後発症したEpstein-Barrウイルス関連リンパ増殖症にドナーリンパ球輸注が奏効した急性リンパ性白血病
  • 症例 HLA1座不適合同胞間同種骨髄移植後発症したEpstein-Barrウイルス関連リンパ増殖症にドナーリンパ球輸注が奏効した急性リンパ性白血病
  • ショウレイ HLA1ザフテキゴウ ドウホウ カン ドウシュ コツズイ イショク ゴ ハッショウ シタ Epstein Barr ウイルス カンレン リンパ ゾウショクショウ ニ ドナーリンパキュウユチュウ ガ ソウコウ シタ キュウセイ リンパセイ ハッケツビョウ

Search this article

Abstract

We report a case of Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD) after allogeneic bone marrow transplantation (allo-BMT) from a partially mismatched related donor for acute lymphocytic leukemia, which was treated successfully by donor lymphocyte infusion (DLI). A 54-year-old woman in first complete remission from acute lymphocytic leukemia received an unmanipulated bone marrow transplant from an HLA-A 1-locus-mismatched sibling donor after precon-ditioning with cyclophosphamide and total body irradiation. Prophylaxis against graft-versus-host disease (GVHD) was done with tacrolimus and short-term methotrexate. Skin GVHD (grade I) occurred on day 36, but this subsided spontaneously without treatment. On day 61, rapidly progressive cervical lymphadenopathy with fever developed. Lymph node biopsy revealed lymphoid cell proliferation, which was positive for LCA, L26 and LMP-1. A diagnosis of EBV-LPD was made. After withdrawal of the tacrolimus, DLI (1×106 CD3 cells/kg) resulted in remission. This case suggests that even in the absence of risk factors such as severe GVHD, intensive immunosuppressive therapy and ATG administration, allo-BMT from an HLA 1-locus-mismatched related donor can be complicated by EBV-LPD, and that reduction of immunosuppressive therapy and DLI can be an effective treatment for it.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 42 (11), 1105-1110, 2001

    The Japanese Society of Hematology

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top